Tumor heterogeneity and microenvironment in pediatric and adult liver cancers

Hosted by María Arechederra
With the participation of Jessica Zucman-Rossi, Carmen Berasain and Matías Ávila during the Q&A

Dr Theo Hirsch is a young researcher studying genomics of liver cancer in the FunGeST team – Functional Genomics of Solid Tumors – led by Pr Jessica Zucman-Rossi in the Cordeliers Research Center (Inserm) in Paris, France.

After a PhD in Cell Biology (studying prion diseases in the lab of Sophie Mouillet-Richard in Paris Descartes University), Dr Hirsch joined the FunGeST team in 2017 to study cancer genomics with a bioinformatic approach and a focus on tumor heterogeneity and microenvironment. Recently, he was involved in the identification of a group of adult hepatocellular carcinomas driven by BAP1 alterations and harboring fibrolamellar-like features (Hirsch*, Negulescu* et al, J Hepatol 2020).

Dr Hirsch is also working on pediatric liver tumors, with a first study deciphering the peculiar immune infiltration induced by cisplatin-based chemotherapy in hepatoblastomas specifically developed in patients with germline APC mutations (Morcrette*, Hirsch*, Badour* et al, Oncoimmunology 2019). Dr Hirsch is currently involved in an integrated multi-omics analysis of an important cohort of pediatric liver cancers (hepatoblastomas, hepatocellular carcinomas, fibrolamellar carcinomas) with a focus on the mechanisms of tumor plasticity and resistance to chemotherapy.”